FDA Grants Orphan Drug Designation To TapImmune Inc. TPIV 200 In The Treatment Of Ovarian Cancer September 29, 2016 cancer immunotherapeutics Inc. (TPIV) Office of Orphan Products Development OOPD Orphan Drug Designation peptide TapImmune TPIV 200 +